In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visterra Inc.

Division of Otsuka Holdings Co. Ltd.
www.visterrainc.com

Latest From Visterra Inc.

Finance Watch: Here Come The IPOs Again As Bellus Raises $70m And Vir Joins The Queue

Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.

Financing Business Strategies

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

Deals Business Strategies

Affinivax’s MAPS Vaccine Technology Reaches Clinic In Under Five Years

Funded entirely by grants and partnerships to date, Affinivax’s pneumococcal vaccine candidate has begun a Phase I/II study less than five year’s after the biotech’s founding. Firm thinks its technology may eventually apply to immuno-oncology as well.

Vaccines Clinical Trials

Japan 2018 Review: Takeda/Shire Dominates But Pharma Life Goes On

2018 in Japan wasn't all about Takeda and Shire - though it mostly was. Amid a generally quiet year for M&A otherwise, companies concentrated on honing their specialty focus, dealing with major patent expiries, and fretting about big changes to the country's pricing system.

Japan Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Parasol Therapeutics
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Otsuka Holdings Co. Ltd.
  • Senior Management
  • Brian Pereira, MD, Pres. & CEO
    Greg Miller, VP, Bus. Dev. & Strategic Planning
    Zachary Shriver, PhD, CSO
    Todd Curtis, VP, Fin.
  • Contact Info
  • Visterra Inc.
    Phone: (617) 498-1070
    275 2nd Ave.
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register